To assess the clinical significance of hnRNPA2B1 in patients with GC, we investigated the hnRNPA2B1 expression levels across different SUVmax values, an indicator of tumor glycolytic metabolism measured via PET/CT (18F‐FDG, 18F‐fluorodeoxyglucose) scans in GC. Here, HNRNPA2B1 is linked to gastric cancer.